TY - JOUR
T1 - DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine :
T2 - A multicentre retrospective study
AU - Noguera-Castells, Aleix
AU - Campillo-Marcos, Ignacio
AU - Davalos, Veronica
AU - García-Prieto, Carlos A
AU - Valcárcel, David
AU - Molero, Antonieta
AU - Palomo Sanchís, Laura
AU - Gattermann, Norbert
AU - Wulfert, Michael
AU - Chaparro-González, Lorea
AU - Sole, F
AU - Cabezón, Marta
AU - Jiménez-Lorenzo, María J.
AU - Xicoy, Blanca
AU - Zamora, Lurdes
AU - De Stefano, Alessia
AU - Casalin, Irene
AU - Finelli, C.
AU - Follo, Matilde Y.
AU - Esteller, M.
PY - 2024/3/12
Y1 - 2024/3/12
N2 - Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by characterizing the epigenomic profiles of patients with MDS treated with azacitidine. Our approach provides a comprehensive view of the evolving DNA methylation architecture of the disease and holds great potential for advancing our understanding of MDS treatment responses to HMAs.
AB - Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by characterizing the epigenomic profiles of patients with MDS treated with azacitidine. Our approach provides a comprehensive view of the evolving DNA methylation architecture of the disease and holds great potential for advancing our understanding of MDS treatment responses to HMAs.
KW - Azacitidine
KW - DNA methylation
KW - Hypomethylating agents
KW - Myelodysplastic syndromes
UR - https://www.scopus.com/pages/publications/85187417459
UR - https://www.mendeley.com/catalogue/5cd961d5-7fa6-3be2-81af-fa1e0468c13a/
U2 - 10.1111/bjh.19392
DO - 10.1111/bjh.19392
M3 - Article
C2 - 38471524
SN - 0007-1048
VL - 204
SP - 1838
EP - 1843
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -